HC Wainwright Reiterates Buy Rating for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $10.00 price objective on the biopharmaceutical company's stock.

Other equities research analysts also recently issued research reports about the company. StockNews.com raised Regulus Therapeutics to a "sell" rating in a report on Tuesday, September 17th. Oppenheimer reissued an "outperform" rating and set a $7.00 target price on shares of Regulus Therapeutics in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $10.80.

Regulus Therapeutics Stock Performance

NASDAQ:RGLS traded down $0.05 during trading hours on Wednesday, hitting $1.56. The stock had a trading volume of 820,188 shares, compared to its average volume of 1,297,783. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79. The company has a market cap of $102.13 million, a price-to-earnings ratio of -1.24 and a beta of 1.62. The business's 50 day moving average is $1.59 and its 200-day moving average is $1.87.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.17). On average, sell-side analysts anticipate that Regulus Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. CVI Holdings LLC bought a new stake in Regulus Therapeutics in the first quarter valued at approximately $4,050,000. Vanguard Group Inc. boosted its holdings in Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company's stock valued at $2,132,000 after acquiring an additional 453,784 shares during the last quarter. NEA Management Company LLC acquired a new position in Regulus Therapeutics in the first quarter valued at approximately $18,627,000. RA Capital Management L.P. acquired a new position in Regulus Therapeutics in the first quarter valued at approximately $18,000,000. Finally, Opaleye Management Inc. acquired a new position in Regulus Therapeutics in the first quarter valued at approximately $490,000. 92.38% of the stock is currently owned by institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.